Abound Wealth Management Supernus Pharmaceuticals, Inc. Transaction History
Abound Wealth Management
- $300 Billion
- Q1 2025
A detailed history of Abound Wealth Management transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Abound Wealth Management holds 4 shares of SUPN stock, worth $121. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4
Previous 6
33.33%
Holding current value
$121
Previous $217,000
39.63%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SUPN
# of Institutions
301Shares Held
60.7MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$315 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$186 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$146 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$87.2 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$79.6 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.62B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...